Pluristem Therapeutics Inc. is an Israel-based clinical-stage regenerative medicine company
using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to
develop cell therapies for inflammation, muscle injuries, hematological deficiencies, and
radiation exposure.
Pluristem’s vision is to leverage its advanced technology and position as a global leader in cell
therapy to develop and market highly effective cell products that will heal patients worldwide.
They strive to achieve this vision by developing powerful cell therapies that can be successfully
commercialized to reach patients who need innovative treatment options.

Pluristem aims to provide patients, physicians, and healthcare systems around the globe with
standardized, easy-to-use, and highly effective PLX cell products that need no genetic or tissue
matching before administration. The Company is active with many respectful regulatory
agencies worldwide to advance its clinical programs towards marketing.

Clinical Programs

Pluristem’s leading programs in Muscle regeneration following hip fracture surgery and Acute
Respiratory Distress Syndrome (ARDS) associated with COVID-19 are in advanced stages of
development. Earlier stage clinical programs include a Phase I study in incomplete recovery
following bone marrow transplantation, and a Phase II study in chronic Graft Versus Host
Disease (cGvHD).

Pluristem is committed to working with corporate strategic partners, medical organizations, and
academic institutions to enhance the global reach of their PLX product portfolio.

Partners and collaborators include:
● NASA’s Ames Research Center
● The U.S. National Institute of Allergy and Infectious Diseases (NIAID)
● U.S. Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute
● Chart Industries
● Thermo Fisher Scientific
● Cha Biotech
● kENUP Foundation
● Abu Dhabi Stem Cells Center (ADSCC)
● A variety of academic partners from around the globe
(https://www.pluristem.com/academic-collaborations/)

Recent News and Milestones:

July 19, 2021: Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board
of Directors

Jul 08, 2021: Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical
Readout

May 25, 2021: Pluristem to Receive €20M Non-Dilutive Funding from the European Investment
Bank

Apr 29, 2021: Pluristem reports positive topline Phase I results in innovative hematology
program, which is first to study PLX-R18 in humans

For full news articles: https://www.pluristem.com/news/

Stock Market: Pluristem Therapeutics Inc. is publicly traded in the NASDAQ under the ticker symbol PSTI as
well as on the TASE.